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Abstract
The penta-ethyl ester prodrug of the chelating agent diethylene triamine pentaacetic acid (DTPA) 
referred to as C2E5, is being developed as an orally bioavailable radionuclide decorporation agent. 
The predicted human efficacy obtained in these experimental animals is confounded by 
interspecies variations of metabolism. Therefore, in the present study, carboxylesterase-mediated 
metabolism of [14C]-C2E5 was compared in the S9 intestinal and hepatic fractions of human, dog 
and rat and their respective plasma. Intestinal hydrolysis of C2E5, resulting in the formation of the 
tetraethyl ester of DTPA (C2E4), was only detected in human and rat. The primary metabolite in 
human and dog hepatic fractions was C2E4 whereas the predominant species identified in rat 
hepatic fractions was the triethyl ester (C2E3). Hepatic hydrolysis of C2E5 causes the formation 
of C2E4 in human, dog and rat and C2E3 in rat only. Minimal C2E5 hydrolysis was observed in 
human and dog plasma whereas in rat plasma C2E5 converted to C2E3 rapidly, followed by 
slower further metabolism. Both recombinant CES1 and CES2 play roles in C2E5 metabolism. 
Together, these data suggest that dogs may be the most appropriate species for predicting human 
C2E5 metabolism whereas rats might be useful for clarifying the potential toxicity of C2E5 
metabolites.
Introduction
The development of medical countermeasures is a national security priority due to the 
diversion of radioactive materials and the threat of nuclear terrorism. A number of potential 
terrorist threat scenarios have been envisioned, including the deployment of a Radiological 
Dispersal Device (“dirty bomb”) that spreads radioactive material over a large populated 
area. Of particular concern are isotopes of the transuranic elements americium (Am), 
plutonium (Pu), and curium (Cm) due to their abundance and availability. The National 
Institutes of Health has been leading an effort to identify innovative therapies that can be 
included in the US Strategic National Stockpile for distribution to populations affected by an 
act of nuclear terrorism. The current strategy to reduce the absorbed radiation dose involves 
decorporation therapy to accelerate excretion of the contaminating radionuclide 1,2. 
Intravenous (i.v.) administration of either the calcium or zinc salts of diethylene triamine 
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pentaacetic acid (Ca-DTPA/Zn-DTPA) has been approved by the US Food and Drug 
Administration (FDA) for contamination with Am, Pu, or Cm 3. To improve access to 
treatment, there is considerable interest in developing orally bioavailable chelators for the 
actinides. As a Class III compound in the Biopharmaceutics Classification System (high 
solubility, low permeability), DTPA is not a good candidate for oral delivery and can only be 
effectively given by i.v. administration.
Introduction of an ester linkage has been shown to enhance the systemic delivery of 
pharmacologically active compounds with low oral absorption due to high hydrophilicity 4-6. 
Therefore, in order to achieve higher oral bioavailability, a penta-ethyl ester DTPA prodrug, 
designated as C2E5, was synthesized. The five added ester moieties greatly increase the 
lipophilicity of DTPA, which is measured by increased CLogP. (CLogP of -2.7 for DTPA in 
contrast to ClogP of 4.7 to C2E5) Studies in rats confirmed that C2E5 shows enhanced oral 
bioavailability compared to DTPA, with extensive but incomplete metabolism 7 and can 
elicit effective radionuclide decorporation following oral 8 and transdermal delivery 9. 
Together, these findings suggest that this prodrug may be a useful and effective alternative 
treatment to DTPA. The enzymes responsible for C2E5 metabolism to DTPA have not 
previously been reported, but promising candidates for metabolism are the 
Carboxylesterases (CESs), which could sequentially cleave the five ester moieties to form 
the metabolites C2E4, C2E3, C2E2, C2E1, and DTPA as shown in Figure 1.
Many of the ester-based prodrugs are biotransformed by carboxylesterases (CESs) (EC 
3.1.1.1), which are members of the α/β-fold hydrolase superfamily. CESs are grouped in five 
subfamilies (CES1–CES5) according to the homology of the amino acid sequence 10,11. The 
most prolific CESs belong to the CES1 and CES2 families, and are categorized as phase I 
enzymes important for metabolism of xenobiotics, including drugs and prodrugs. All CESs 
cleave esters via a two-step process that involves the formation and degradation of an acyl-
enzyme intermediate. CESs exhibit ubiquitous tissue expression, but are predominantly 
expressed within the small intestine and liver consistent with their roles in biotransformation 
and detoxification. Carboxylesterase expression differs among species and organs within a 
single species, resulting in differences in substrate specificity 12,13. For example, rat plasma 
has high expression of CES whereas the human and dog are lacking of CES activities 14. In 
addition to the differences in expression, species differences exist regarding to CES activity. 
In general, it has been shown that CES2 has much greater affinity for lipophilic substrates 
compared to CES1 13; meanwhile, CES1 prefers small alcohol group compound and CES2 
prefers bigger alcohol group compound. Those characteristics of CESs could have important 
implications for lipophilic ester prodrugs, such as C2E5.
The increasing threat of nuclear and biological terrorism has led the FDA to expedite the 
development and approval of new drug and biological products. The Animal Efficacy Rule 
(21 C.F.R. § 314.610, drugs) 16,17 states, “when efficacy studies in humans are unethical or 
infeasible, studies in animal models will typically be needed to provide the efficacy data 
required to support approval, licensure, clearance, or emergency authorization.” As new 
therapies are being developed that utilize these hydrolytic pathways, it is vital to understand 
the similarities and differences in CES activity between humans and preclinical models of 
drug disposition 18. Thus, establishment of a reliable animal model for assessing the efficacy 
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of radionuclide decorporation therapy is critical. The goal of the current study was to 
identify potential species and tissue differences in the CES-mediated hydrolysis of the multi-
ester prodrug C2E5.
Material and Methods
Chemicals and Materials
[14C]-diethylene triamine pentaacetic acid pentaethyl ester ([14C]-C2E5; 50 mCi/mmol) was 
purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Sprague-Dawley 
rat intestinal S9 fractions, isolated from a single male were purchased from Celsis In Vitro 
Technologies (Baltimore, MD). Pooled, mixed gender human (intestinal, hepatic), single 
male Beagle dog (intestinal, hepatic), and single male Sprague-Dawley (hepatic) S9 
fractions were purchased from Xenotech, LLC (Lenexa, KS). All S9 fractions were prepared 
in the absence of phenylmethanesulfonylfluoride. Human CES1 and CES2 supersomes were 
obtained from BD Biosciences (Woburn, MA). Human, Beagle dog, and Sprague-Dawley rat 
plasma was purchased from Lampire Biological Laboratories, Inc. (Pipersville, PA). Ultima-
Flo AP scintillation fluid was obtained from PerkinElmer Life and Analytical Sciences 
(Waltham, MA). Acetonitrile (ACN) and bis-(p-nitrophenyl) phosphate (BNPP) were 
purchased from Sigma Aldrich (St. Louis, MO).
C2E5 In Vitro Metabolism in Human, Dog and Rat Intestinal and Hepatic S9 Fractions and 
Plasma
[14C]-C2E5 (50μM) was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 
37°C. Reactions were initiated by the addition of intestinal or hepatic S9 fractions (1 mg/ml) 
and were maintained at 37°C. Plasma (250 μl reaction volumes) was pre-incubated for 5 min 
at 37°C. Reactions were initiated by the addition of 50 μM [14C]-C2E5 and were maintained 
at 37°C. Equivalent boiled S9 fractions were used as a blank to correct for non-enzymatic 
C2E5 degradation. The reactions were terminated by addition of an equal volume of ice-cold 
ACN followed by centrifugation at 14,000 × g for 10 min at 4°C. The supernatant was 
transferred to HPLC vials for subsequent analysis.
C2E5 Metabolism by Human CES1-b, CES1-c, and CES2
One μM of [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 
37°C. Reactions were initiated by the addition of CES1-b, CES-c and CES2 recombinant 
supersomes. The final enzyme concentration was 1 mg/ml and maintained at 37°C. In all 
instances, equivalent boiled S9 fractions were used as blanks to correct for non-enzymatic 
C2E5 degradation. The reactions were terminated by addition of an equal volume of ice-cold 
ACN followed by centrifugation at 14,000 × g for 10 min at 4°C. The supernatant was 
transferred to HPLC vials for subsequent analysis.
Inhibition Studies on C2E5 metabolite formation
Recombinant human supersomes of CES1-b, CES1-c, and CES2 (final concentration of 1 
mg/ml) were incubated in the absence and presence of the esterase inhibitor bis (4-
nitrophenyl)-phosphate (BNPP) at 100 μM. The final concentration of the organic solvent 
(methanol) was less than 1%.
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HPLC analysis of C2E5 and Metabolites
C2E5 and its metabolites were analyzed using a Shimadzu Prominence HPLC system 
equipped with a Perkin Elmer Radiomatic 625TR Flow Scintillation Analyzer. Two 
Chromolith® Fast Gradient columns (RP-18e 50 × 2 mm Sorbent Lot No. UM8507) were 
used in tandem with an Alltima Alltech HP All-Guard Cartridge (C18, 5 μm particle size, 
2.1 × 7.5 mm). Mobile phase A consisted of water with 0.1% TFA and mobile phase B was 
ACN with 0.1% TFA. Six regions of interest in the radiochromatogram were identified with 
a linear 14-min gradient with a flow rate of 0.3 ml/min, 5-95% B over 8 min before 
returning to 5% B for the remaining six min. Each sample (10 μl) was injected in 
quadruplicate. The activity in each region that met the threshold criteria (peak height greater 
than 60 cpm) was determined and expressed as a percentage of the total activity in all 
regions. The regions of interest were as follows: DTPA, 1.20-2.30 min; C2E1, 3.60-4.90 
min; C2E2, 4.90-5.60 min; C2E3, 5.60-6.50 min; C2E4, 6.50-7.30 min; and C2E5, 
7.30-9.00 min.
Data Analysis
All assays were performed in triplicate and expressed as the mean ± S.D. Data were 
analyzed with one-way ANOVA test by using GraphPad Prism 5 software. (***) is 
designated for P<0.001.
Results
C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Intestinal S9 Fractions
As shown in Fig. 2A, C2E5 hydrolysis was minimal in human intestinal S9 fractions, with 
approximately 84% C2E5 remaining over the 2 h incubation, whereas no hydrolysis 
occurred in the dog intestinal fractions. Rat intestinal fractions metabolized 85% of the 
C2E5. The C2E5 metabolic profile of human, dog and rat fractions was determined by a 
radiomatic HPLC assay and is shown in Figs. 2B-2D. In human intestinal fractions, no 
metabolites were detected at the early time points; however, at 2 h, a modest amount (16%) 
of the activity had been converted to the tetraethyl ester (C2E4) metabolite (Fig. 2B). The 
rapid disappearance of C2E5 in rat intestinal fractions coincided with time-dependent C2E4 
formation as early as 10 min (Fig 2D). A minor amount of the triethyl ester (C2E3) was 
observed at later time points.
C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Liver S9 Fractions
As shown in Fig. 3A, C2E5 is rapidly metabolized in liver S9 fractions from all tested 
species. Human and dog S9 fractions hydrolyze approximately 85% of C2E5 within the first 
30 min. No further metabolism was observed over the remainder of the 2 h incubation 
period. Similarly, rat S9 fractions efficiently metabolized greater than 95% of C2E5 over the 
same incubation period. Interestingly, in all three species C2E5 hydrolysis correlated with 
primarily an increase in C2E4. In the case of human and dog fractions (Fig. 3B and 3C), 
C2E4 formation peaked at nearly 80% of the detected activity by 60 min, before a slight 
decrease at the 120 min time point, due to minor increases in C2E3 and the diethyl ester 
(C2E2). In rat fractions, C2E4 formation was complete at 10 min and C2E3 became the 
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predominant metabolite, accounting for nearly 80% of the detected activity, from 15 min 
through the duration of the assay (Fig. 3D).
C2E5 Hydrolysis Catalyzed by Human, Dog and Rat Plasma
Species differences are clearly evident when C2E5 was incubated in plasma of human, dog 
and rat (Fig. 4A). Moderate (∼30%) and no C2E5 hydrolysis were observed in human and 
dog plasma respectively. (Fig. 4A). Human plasma generated only C2E4 as a metabolite 
after 2 h of incubation, comprising approximately 30% of the total activity, while dog 
plasma did not show any detectable metabolites within this time period (Fig. 4B and 4C). In 
contrast, C2E5 was rapidly hydrolyzed in rat plasma and yielded a strikingly different 
metabolic profile, in which C2E4 was the primary metabolite in the first min of incubation 
(Fig. 4D and 4E). The principle metabolite identified within the first 60 min was C2E3 
which accounted for ∼60% of the activity. At the 2 h time point, there are equivalent 
amounts of C2E3, C2E2 and the mono-ethyl ester (C2E1) each accounting for ∼30% of the 
activity. The remaining activity was attributed to C2E4 and DTPA (Fig. 4E).
C2E5 Hydrolysis Catalyzed by Recombinant Human CES1-b, CES1-c and CES2
Incubation of 1μM [14C]-C2E5 with human CES1 or CES2 supersomes are presented in 
Figure 5. These data show that C2E5 was hydrolyzed (∼15%) over 60 min. CES1-b, CES1-c 
and CES2 all contribute to the hydrolysis of C2E5.
Inhibition Studies of C2E5 Metabolism
The inhibition effects of BNPP on C2E5 metabolite formation was investigated (Fig. 6). In 
the presence of the esterase inhibitor BNPP, C2E5 metabolism was significantly reduced in 
recombinant human CES1-b and CES1-c and human liver S9 fractions.
Discussion
The path to FDA approval for treatments against bio- and nuclear-terrorism agents is unique. 
Instead of relying on human studies, the FDA Animal Rule allows approval of drugs that 
have been shown to be effective in animal models in the absence of clinical trials. However, 
the predictive human efficacy obtained in experimental animals is confounded by 
interspecies variations in metabolism. The inhibition effects of the specific esterase inhibitor, 
BNPP, confirmed that C2E5 was mainly cleaved by esterase. Our results provide direct 
evidence that C2E5 is metabolized in a species and tissue dependent manner. Additionally, 
C2E5 metabolism observed in the presence of recombinant human CES isoforms (CES1-b, 
CES1-c and CES2) further supports the role of the CES enzyme system in C2E5 hydrolysis. 
The current study suggests that the dog maybe the best for modeling human C2E5 exposure 
whereas the rat is uniquely useful for clarifying relative capacity of C2E5 to form more 
metabolites.
Intestinal metabolism plays an important role in the bioavailability of oral therapeutic ester 
prodrugs. The expression of intestinal CES is species-dependent. For example, the small 
intestine contains only enzymes from the CES2 family in humans and rats whereas CES2 
expression is lacking in dog13. Consistent with the CES expression profile, C2E5 hydrolysis 
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was absent following incubation in dog intestinal S9 fractions. However, C2E5 hydrolysis 
was minimal in human intestinal fractions whereas rat intestinal fractions almost completely 
hydrolyze C2E5 (Fig. 2B and 2D). The differing rates of metabolism observed in human and 
rat intestinal fractions may be explained, in part, by differential CES isoform expression. 
Humans express only one CES2 isoform, however, rats express one major CES2 (RL4) and 
four minor CESs in the intestine 19. In addition to differing CES expression, it has been 
shown that the intestinal CES2 of rat is markedly more efficient at metabolizing ester-
containing compounds than the human CES213 implying the rapid disappearance of C2E5 in 
rat intestinal fractions is due to the greater ability to hydrolyze C2E513. However, additional 
unidentified enzymes may be responsible for the distinct C2E5 metabolic profile identified 
in rat. Interestingly, in both human and rat intestinal S9 studies, C2E4 was the major 
metabolite. This may be due to the structure-activity relationship between C2E5 and CESs. 
Together, these results suggest that the intestine plays an important role in the CES-mediated 
first-pass metabolism of C2E5 in rats, but not in the dog and only to a small degree in 
human.
CES1 and CES2 are all expressed abundantly in human, dog, and rat liver 20. The degree of 
C2E5 hydrolysis and the resultant metabolic profiles are vastly different between human and 
dog liver S9 fractions compared to rats (Table 1). This could be due to different CES 
expression patterns in rats. The rat liver CES1 family includes 4 different isozymes, 
hydrolase A, hydrolase B, hydrolase C and rat egasyn and three minor CES2 isozymes 
(RL4, AY034877 and D50580). Among them, hydrolase A is the closest to the major human 
CES1 with about 78% homology 21. Observed species-dependent CES expression profile is 
probably responsible for the differences in the metabolism of C2E5 identified in human and 
dog when compared to rat. However, a direct comparison of the full complement of human, 
dog and rat CES isozymes would be needed to confirm these hypotheses.
The formation of DTPA from C2E5 mediated by CES, and possibly other enzymes, appears 
to occur through four intermediates (C2E4, C2E3, C2E2, C2E1) as shown in Figure 1. C2E5 
hydrolysis in S9 fractions suggests CES activities in the intestine and livers are insufficient 
for complete conversion to DTPA (Figs. 2 and 3). Thus, once C2E5, or a resulting 
metabolite, enters the systemic circulation, it is still susceptible to further metabolism by 
esterases present in plasma. Human and dog plasma have little or no detectable CES 
enzyme 15. However, in human plasma there was a moderate level of C2E5 hydrolysis even 
in the absence of CES activity (Fig 4A and 4B). In contrast to human liver and small 
intestine where greater than 90% of esterase activity is attributed to CESs 22, 
butyrylcholinesterase (BuChE), paraoxonase (PON), and albumin esterase, but not CESs, 
possess hydrolytic activity in human plasma 15. Of the three PON isoforms (PON1, PON2, 
PON3), only PON 1 has hydrolytic activity 23. Moreover, PON1 substrate specificity is 
restricted to organophosphate pesticides and nerve gasses 24,25, thus limiting the role that 
PON1 may play in the hydrolysis of C2E5. BuChE and albumin esterase, both of which 
contribute to the activation of prodrugs 26-29 are both likely to contribute to the hydrolysis of 
C2E5 in human plasma. The fact that C2E5 was rapidly hydrolyzed in rat plasma is 
consistent with the presence of relatively high levels of CES activity in rat plasma. This 
represented the most efficient cleavage of the esters resulting in the time-dependent 
formation of multiple metabolites.
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C2E5, a lipophilic compound with a CLogP value of 4.7, was hydrolyzed by recombinant 
protein CES1 and CES2 7. Hydrolysis of C2E5 by CES1 was higher than CES2 at an 
enzyme concentration of 1mg/ml (Fig. 5). The difference in activity is most likely due to the 
structural and conformational differences between CES1 and CES2. Human CES2 has been 
shown to have a greater affinity for lipophilic substrates compared to human CES1, possibly 
due to greater conformational flexibility and a larger entrance to the active site 28, but human 
CES1 prefers substrates with smaller alcohol groups. C2E5, a lipophilic molecule with small 
alcohol groups, possesses attributes that make it suitable for metabolism by both enzymes. 
However, the metabolites of C2E5 might be expected to have an increasing preference for 
CES1 because of the decrease in lipophilicity associated with the cleaving each ester. Any 
difference in metabolism between CES1-b and CES1-c is small because the enzymes are 
structurally very similar. In contrast, CES1 and CES2 share only 48% of sequence 
homology 31. Bis-(4-nitrophenyl) phosphate (BNPP), an inhibitor of CES-mediated 
hydrolysis 32, inhibited C2E5 hydrolysis when added to samples of CES1-b, CES1-c, and 
human liver S9 (Fig 6). This result confirms that human recombinant proteins CESs are 
responsible for the hydrolysis of C2E5. Even though the inhibition is not one hundred 
percent, in all cases these results are consistent with the findings in literature on ester-based 
prodrug studies 32.
During the development of pharmaceutical products, drug disposition and toxicity are 
usually evaluated in several different animal species. For a drug such as C2E5, the FDA 
Animal Rule requires an in depth understanding of differences in metabolic capacities 
among species. In conclusion, we have shown that C2E5 metabolism is species specific due 
to differing CESs expression profiles. Together, the results suggest that the dog is a better 
predictive model for C2E5 metabolism in humans whereas the rat is important for 
understanding the potential toxicity of C2E5 metabolites.
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Figure 1. Proposed carboxylesterase-mediated metabolism of C2E5 to DPTA through four 
intermediates
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Figure 2. C2E5 Hydrolysis by Human, Dog, and Sprague-Dawley Rat Intestinal S9 Fractions
Fifty μM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 
37°C. Reactions were initiated by the addition of intestinal S9 fractions (1 mg/ml final 
concentration) and were incubated at 37°C. The reactions were terminated at the indicated 
time points by addition of an equal volume of cold acetonitrile followed by centrifugation at 
14,000 × g for 10 min at 4°C. The percent (A) C2E5 remaining and (B) human, (C) dog and 
(D) rat metabolic profiles [C2E4 (◆); C2E3 (○); C2E2 (▲); C2E1 (□); DTPA (●)] were 
determined by radio-HPLC. All assays were performed in triplicate and are expressed as the 
mean ± S.D.
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Figure 3. C2E5 Hydrolysis by Human, Dog, and Sprague-Dawley Rat Hepatic S9 Fractions
Fifty μM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 
37°C. Reactions were initiated by the addition of hepatic S9 fractions (1 mg/ml final 
concentration) and were incubated at 37°C. The reactions were terminated at the indicated 
time points by addition of an equal volume of cold acetonitrile followed by centrifugation at 
14,000 × g for 10 min at 4°C. The percent (A) C2E5 remaining and (B) human, (C) dog and 
(D) rat metabolic profiles [C2E4 (◆); C2E3 (○); C2E2 (▲); C2E1 (□); DTPA (●)] were 
determined by radio-HPLC. All assays were performed in triplicate and are expressed as the 
mean ± S.D.
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Figure 4. C2E5 Hydrolysis by Human, Dog, Sprague-Dawley Rat Plasma Fractions
Fifty μM [14C]-C2E5 was added directly to plasma (pre-warmed for 5 min at 37°C). The 
reactions were terminated at the indicated time points by addition of an equal volume of cold 
acetonitrile followed by centrifugation (2X) at 14,000 × g for 10 min at 4°C. The percent 
(A) C2E5 remaining and (B) human, (C) dog and (D, E) rat metabolic profiles [C2E4 (◆); 
C2E3 (○); C2E2 (▲); C2E1 (□); DTPA (●)] were determined by radio-HPLC. All assays 
were performed in triplicate and were expressed as the mean ± S.D.
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Figure 5. C2E5 Hydrolysis by CES1-b, CES1-c and CES2
One μM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 5 min at 
37°C. Reactions were initiated by the addition of recombinant supersomes (1 mg/ml final 
concentration) and were incubated at 37°C. The reactions were terminated at the indicated 
time points by addition of an equal volume of cold acetonitrile followed by centrifugation at 
14,000 × g for 10 min at 4°C. The disappearance of C2E5 was determined by radio-HPLC.
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Figure 6. Inhibition Studies on C2E5 Hydrolysis
Fifty μM [14C]-C2E5 was pre-incubated in 0.1 M phosphate buffer (pH 7.4) for 15 min at 
37°C with addition of 100 uM BNPP. Reactions were initiated by the addition of 
recombinant supersomes (1 mg/ml final concentration) and were incubated at 37°C. The 
reactions were terminated at the indicated time points by addition of an equal volume of cold 
acetonitrile followed by centrifugation at 14,000 × g for 10 min at 4°C. The disappearance 
of C2E5 was determined by radio-HPLC.
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Table 1
Metabolites of C2E5 Identified in Human, Dog and Rat S9 and Plasma Fraction
Species Intestine S9 Hepatic S9 Recombinant S9 Plasma
Human C2E4 C2E4 C2E4, C2E3, DTPA C2E4
Dog ND C2E4 N/A ND
Rat C2E4 C2E4, C2E3, C2E2 N/A C2E4, C2E3, C2E2, C2E1, DTPA
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